Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ARGONAUT

Financiado

Cerrado

ARGONAUT from the synthesis of gAnglioside tumouR antiGens to a platfOrm for ca...

ARGONAUT from the synthesis of gAnglioside tumouR antiGens to a platfOrm for caNcer Active immUnoTherapy Immunotherapy is currently revolutionizing cancer therapy by harnessing the power of the innate and adaptive immune system against cancer cells, thus providing a more tumour-selective approach in assistance to traditional treatmen... ver más

31/07/2021

TECHNICAL UNIVERSI...

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-31

MSCA-IF-2018: Individual Fellowships

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

TECHNICAL UNIVERSITY OF DENM...

207.31K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SweetCAR CAR T cell therapy targeting carbohydrates in cancer 150K€ Cerrado

SweetAim Selective glycoimmuno targeting for cancer therapy 1M€ Cerrado

GlycoTherapy New frontiers in advanced glycotherapy for cancer 2M€ Cerrado

MGLycan Targeting hMGL GalNAc interactions to reverse immune suppres... 173K€ Cerrado

InnoTACA Innovation Associate for highly specific Tumour Associated C... 100K€ Cerrado

PanCaVax Personalised Pancreatic Cancer Vaccination Therapy derived f... 71K€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2019-04-11
Fecha Fin: 2021-07-31

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 207K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immunotherapy is currently revolutionizing cancer therapy by harnessing the power of the innate and adaptive immune system against cancer cells, thus providing a more tumour-selective approach in assistance to traditional treatments. The identification of tumour-associated carbohydrate antigens (TACAs), aberrant types of glycans decorating the surface of tumour cells, has paved the way for the development of new types of cancer vaccines. However, while significant progress has been made in this area of research, TACA-based cancer vaccines have not yet reached the clinic. In this context, ARGONAUT will address some limitations that characterize classical approaches in carbohydrate cancer vaccine development, with the overall aim of establishing a strategy to access novel, more effective, and fully synthetic vaccine candidates. ARGONAUT’s journey aims at the preparation of vaccine candidates based on ganglioside-type TACAs (expressed in melanoma, neuroblastoma, and small cell lung cancer) that are easy to formulate, able to elicit a immune response independent from individual polymorphisms, and with better chances to reach the clinical environment. Employing a synthetic carbohydrate chemistry approach, ARGONAUT explores its application as a tool to contribute to H2020 European efforts in cancer research, while providing excellent training in a multidisciplinary and intersectoral environment through a well-implemented work-plan. From another perspective, ARGONAUT’s impact will also benefit from the transfer of knowledge to the host institution with the establishment of a new research line in active cancer immunotherapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores